Reviewing GeneDx (NASDAQ:WGS) and bioMerieux (OTCMKTS:BMXMF)

bioMerieux (OTCMKTS:BMXMF) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Profitability

This table compares bioMerieux and GeneDx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioMerieux	N/A	N/A	N/A
GeneDx	-4.92%	14.73%	8.67%

Volatility & Risk

bioMerieux has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500.

Valuation and Earnings

This table compares bioMerieux and GeneDx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioMerieux	$4.60 billion	2.63	$449.73 million	N/A	N/A
GeneDx	$427.54 million	4.54	-$21.02 million	($0.75)	-88.27

bioMerieux has higher revenue and earnings than GeneDx.

Insider and Institutional Ownership

61.7% of GeneDx shares are owned by institutional investors. 29.6% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for bioMerieux and GeneDx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioMerieux	0	2	0	0	2.00
GeneDx	1	0	7	1	2.89

GeneDx has a consensus target price of $140.71, indicating a potential upside of 112.56%. Given GeneDx’s stronger consensus rating and higher probable upside, analysts plainly believe GeneDx is more favorable than bioMerieux.

Summary

GeneDx beats bioMerieux on 10 of the 13 factors compared between the two stocks.

About bioMerieux

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.